The Latin America, Middle East and Africa Idiopathic Pulmonary Fibrosis Market would witness market growth of 12.3% CAGR during the forecast period (2021-2027).
Idiopathic pulmonary fibrosis affects only one person in a family in the majority of cases. These are described as sporadic cases. A small number of persons with this disease, however, have at least one other family member who is also affected. Familial pulmonary fibrosis develops when idiopathic pulmonary fibrosis affects numerous members of the same family. Moreover, IPF has no known treatment at this time. Certain medications, on the other hand, may reduce the progress of IPF, thereby extending people's lives and improving their quality of life.
Increased use of the costly Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favor of off-label pharmacological therapy and non-pharmacological treatments has been the key driver for the industry. In addition, despite negative recommendations in evidence-based guidelines for general treatment, cheap corticosteroids and immunosuppressants were used to treat IPF prior to the approval of these medications.
In many countries of the region, healthcare spending per capita is rising. The desire and ability of people to spend on the health has resulted in a small increase in pharmaceutical spending. The total rise of the healthcare industry can be ascribed to factors such as rapid economic growth and rising disposable income. Increased demand for innovative drugs/therapies for pulmonary fibrosis is likely to arise from rising pharmaceutical spending. However, high cost for the treatment of idiopathic pulmonary fibrosis would discourage many people in the region to pursue healthcare goals. Smoking is becoming more common in both developed and developing countries.
In 2018, it was predicted that 9.3 percent of the 157.2 million Brazilians aged 18 and up smoked (12.1 percent males and 6.2 percent females). In the same year, 2.4 percent of adults were classified as heavy smokers (those who smoke 20 cigarettes or more per day), while 7.6 percent of adults were exposed to passive smoking at home and 6.8% at work. According to the WHO, the prevalence of smoking is higher in upper-middle-income countries than in high-income ones.
The Brazil market dominated the LAMEA Idiopathic Pulmonary Fibrosis Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $72.1 million by 2027. The Argentina market is anticipated to grow at a CAGR of 12.9% during (2021 - 2027). Additionally, The UAE market would expect a CAGR of 12% during (2021 - 2027).
Based on Drug Type, the market is segmented into Pirfenidone and Nintedanib. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Idiopathic Pulmonary Fibrosis Market is Predict to reach $4.7 Billion by 2027, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- GNI Group Ltd.
- Shionogi & Co., Ltd.
- Mission Therapeutics Ltd.
- Galapagos NV
- FibroGen, Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Biogen, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Idiopathic Pulmonary Fibrosis Market, by Drug Type
1.4.2 LAMEA Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
1.4.3 LAMEA Idiopathic Pulmonary Fibrosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
Chapter 4. LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type
4.1 LAMEA Pirfenidone Market by Country
4.2 LAMEA Nintedanib Market by Country
Chapter 5. LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel
5.1 LAMEA Retail Pharmacies Market by Country
5.2 LAMEA Hospital Pharmacies Market by Country
5.3 LAMEA Online Providers Market by Country
Chapter 6. LAMEA Idiopathic Pulmonary Fibrosis Market by Country
6.1 Brazil Idiopathic Pulmonary Fibrosis Market
6.1.1 Brazil Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.2 Brazil Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2 Argentina Idiopathic Pulmonary Fibrosis Market
6.2.1 Argentina Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.2 Argentina Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3 UAE Idiopathic Pulmonary Fibrosis Market
6.3.1 UAE Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.2 UAE Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4 Saudi Arabia Idiopathic Pulmonary Fibrosis Market
6.4.1 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.2 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.5 South Africa Idiopathic Pulmonary Fibrosis Market
6.5.1 South Africa Idiopathic Pulmonary Fibrosis Market by Drug Type
6.5.2 South Africa Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.6 Nigeria Idiopathic Pulmonary Fibrosis Market
6.6.1 Nigeria Idiopathic Pulmonary Fibrosis Market by Drug Type
6.6.2 Nigeria Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.7 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market
6.7.1 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type
6.7.2 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 GNI Group Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Shionogi & Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Mission Therapeutics Ltd.
7.3.1 Company Overview
7.4 Galapagos NV
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 FibroGen, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals and Trials:
7.7.5.2 Acquisitions and Mergers:
7.8 Bristol Myers Squibb Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. Biogen, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
TABLE 1 LAMEA Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 2 LAMEA Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements – Idiopathic Pulmonary Fibrosis Market
TABLE 4 Approvals and Trials – Idiopathic Pulmonary Fibrosis Market
TABLE 5 Acquisition and Mergers – Idiopathic Pulmonary Fibrosis Market
TABLE 6 LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 7 LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 8 LAMEA Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 9 LAMEA Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 10 LAMEA Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 11 LAMEA Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 12 LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 13 LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 14 LAMEA Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 15 LAMEA Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 16 LAMEA Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 17 LAMEA Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 18 LAMEA Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 19 LAMEA Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 20 LAMEA Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 21 LAMEA Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 22 Brazil Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 23 Brazil Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 24 Brazil Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 25 Brazil Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 26 Brazil Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 27 Brazil Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 28 Argentina Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 29 Argentina Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 30 Argentina Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 31 Argentina Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 32 Argentina Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 33 Argentina Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 34 UAE Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 35 UAE Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 36 UAE Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 37 UAE Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 38 UAE Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 39 UAE Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 40 Saudi Arabia Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 41 Saudi Arabia Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 42 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 43 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 44 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 45 Saudi Arabia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 46 South Africa Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 47 South Africa Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 48 South Africa Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 49 South Africa Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 50 South Africa Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 51 South Africa Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 52 Nigeria Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 53 Nigeria Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 54 Nigeria Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 55 Nigeria Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 56 Nigeria Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 57 Nigeria Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 58 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 59 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 60 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 61 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 62 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 63 Rest of LAMEA Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 64 Key Information – GNI Group Ltd.
TABLE 65 Key Information – Shionogi & Co., Ltd.
TABLE 66 Key Information – Mission Therapeutics Ltd.
TABLE 67 Key Information – Galapagos NV
TABLE 68 Key Information – FibroGen, Inc.
TABLE 69 Key Information – AstraZeneca PLC
TABLE 70 key information – F. Hoffmann-La Roche Ltd.
TABLE 71 Key Information – Bristol Myers Squibb Company
TABLE 72 Key Information – Boehringer Ingelheim International GmbH
TABLE 73 Key Information – Biogen, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.